For patients with MET-altered NSCLC, several MET TKIs have shown therapeutic activities against these tumors.13, 14, 15 Recently, combination therapy with EGFR TKI and MET TKI has revealed efficacy in patients with MET-overexpressed or amplified, EGFR-mutant NSCLC with disease progression on prior EGFR TKI.16, 17, 18 Nevertheless, treatment response and diagnostic criteria of MET alterations varied between different studies. The gene discussed is MET; the disease is non-small cell lung carcinoma.